Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis

BACKGROUND: Tegoprazan is a novel potassium‐competitive acid blocker that has a fast onset of action and can control gastric pH for a prolonged period, which could offer clinical benefit in acid‐related disorders. AIM: To confirm the non‐inferiority of tegoprazan to esomeprazole in patients with ero...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Aliment Pharmacol Ther
Hlavní autoři: Lee, Kwang Jae, Son, Byoung Kwan, Kim, Gwang Ha, Jung, Hye‐Kyung, Jung, Hwoon‐Yong, Chung, Il‐Kwun, Sung, In‐Kyung, Kim, Jin Il, Kim, Jong Hyeok, Lee, Joon Seong, Kwon, Joong Goo, Park, Jung Ho, Huh, Kyu Chan, Park, Kyung Sik, Park, Moo‐In, Kim, Nayoung, Lee, Oh Young, Jee, Sam Ryong, Lee, Sang Kil, Youn, Sei Jin, Kim, Sung Kook, Lee, Soo Teik, Hong, Su Jin, Choi, Suck Chei, Kim, Tae Nyeun, Youn, Young Hoon, Park, Hyo Ju, Kang, Min Ja, Park, Chi Hye, Kim, Bong Tae, Youn, Sangjun, Song, Geun Seog, Rhee, Poong‐Lyul
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Randomised Clinical Trial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594096/
https://ncbi.nlm.nih.gov/pubmed/30843245
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15185
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky